Mustafa S Jamal, Nadeem Ahmed, Fan Ming, Zhong Hongyan, Belardinelli Luiz, Zeng Dewan
Department of Physiology and Pharmacology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.
J Pharmacol Exp Ther. 2007 Mar;320(3):1246-51. doi: 10.1124/jpet.106.112250. Epub 2006 Dec 11.
It has been previously proposed that adenosine plays an important role in the pathogenesis of asthma. The proposed mechanism of action for nucleoside adenosine is to activate A(2B) adenosine receptors (AR) and to indirectly modulate levels of mediators in the lung. In vivo data supporting the role of A(2B) AR in airway reactivity and inflammation in allergic animal models are lacking. The present study describes the effects of a selective A(2B) AR antagonist, CVT-6883 [3-ethyl-1-propyl-8-[1-(3-trifluoromethylbenzyl)-1H-pyrazol-4-yl]-3,7-dihydropurine-2,6-dione], on airway reactivity and inflammation in an allergic mouse model of asthma. Mice were sensitized with ragweed (i.p.) on days 1 and 6 and challenged with 0.5% ragweed on days 11, 12, and 13. On day 14, airway reactivity to 5'-N-ethylcarboxamidoadenosine (NECA), AMP, or allergen challenge was measured in terms of enhanced pause (Penh). Aerosolized NECA elicited concentration-dependent increases in Penh, which were significantly attenuated by CVT-6883 (0.4, 1.0, or 2.5 mg/kg i.p.). Aerosolized AMP elicited significant increases in Penh in sensitized mice, and the effect was significantly attenuated by either CVT-6883 (1 mg/kg i.p.) or montelukast (1 mg/kg i.p.). Allergen challenge induced late allergic response in sensitized mice, which was inhibited by CVT-6883 (1 mg/kg i.p.). Allergen challenge also increased the number of cells in bronchoalveolar lavage fluid obtained from sensitized mice, and that was reduced by either CVT-6883 (6 mg/ml aerosolization for 5 min) or theophylline (36 mg/ml aerosolization for 5 min). These results suggest that A(2B)AR antagonism plays an important role in inhibition of airway reactivity and inflammation in this model of allergic asthma.
先前有人提出,腺苷在哮喘发病机制中起重要作用。核苷腺苷的作用机制是激活A(2B)腺苷受体(AR)并间接调节肺中介质的水平。缺乏支持A(2B) AR在过敏性动物模型的气道反应性和炎症中作用的体内数据。本研究描述了选择性A(2B) AR拮抗剂CVT-6883 [3-乙基-1-丙基-8-[1-(3-三氟甲基苄基)-1H-吡唑-4-基]-3,7-二氢嘌呤-2,6-二酮]对哮喘过敏性小鼠模型气道反应性和炎症的影响。在第1天和第6天用豚草(腹腔注射)使小鼠致敏,并在第11、12和13天用0.5%豚草进行激发。在第14天,根据增强间歇(Penh)测量气道对5'-N-乙基羧酰胺腺苷(NECA)、AMP或变应原激发的反应性。雾化的NECA引起Penh浓度依赖性增加,CVT-6883(腹腔注射0.4、1.0或2.5 mg/kg)可显著减弱这种增加。雾化的AMP在致敏小鼠中引起Penh显著增加,CVT-6883(腹腔注射1 mg/kg)或孟鲁司特(腹腔注射1 mg/kg)可显著减弱这种作用。变应原激发在致敏小鼠中诱导迟发性过敏反应,CVT-6883(腹腔注射1 mg/kg)可抑制该反应。变应原激发还增加了从致敏小鼠获得的支气管肺泡灌洗液中的细胞数量,CVT-6883(雾化6 mg/ml,持续5分钟)或茶碱(雾化36 mg/ml,持续5分钟)可减少该数量。这些结果表明,在该过敏性哮喘模型中,A(2B)AR拮抗作用在抑制气道反应性和炎症中起重要作用。